Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationPaul B. Chapman, Grant A. McArthur, Axel Hauschild et al.|New England Journal of Medicine|2011Cited by 7.7k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III MelanomaAlexander M.M. Eggermont, Caroline Robert|New England Journal of Medicine|2018Cited by 1.8k
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant TherapyAlexander M.M. Eggermont, Alessandro Testori|New England Journal of Medicine|2016Cited by 1.3k
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyGrant A. McArthur, Axel Hauschild, Paul B. Chapman et al.|The Lancet Oncology|2014Cited by 978
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trialAlexander M.M. Eggermont, Ulrich Keilholz, Stefan Suciu et al.|The Lancet|2008Cited by 642